Want to see TSE:EPRX full AI Analyst Report?
EPRX Stock Chart & Stats
C$10.20
C$0.52(6.33%)
At close: 4:00 PM EDT
C$10.20
C$0.52(6.33%)
Day’s Range― - ―
52-Week RangeC$7.35 - C$13.08
Previous CloseN/A
Volume54.38K
Average Volume (3M)91.33K
Market Cap
C$712.55M
Enterprise ValueC$469.12M
Total Cash (Recent Filing)C$133.44M
Total Debt (Recent Filing)C$1.84M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Nov 11, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.02
Shares Outstanding65,906,630
10 Day Avg. Volume79,170
30 Day Avg. Volume91,335
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)5.04
Price to Sales (P/S)0.00
P/FCF Ratio-13.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$23.91Price Target Upside134.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.88
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Local-delivery PlatformThe DiffuSphere platform provides a differentiated development foundation by targeting localized, extended-release treatment. If clinical results support its design goals, the technology could enable repeatable product development across several indications while potentially improving tolerability and treatment convenience.
Clinical Execution MilestoneReaching the RESOLVE enrollment target is a meaningful execution milestone for a clinical-stage company. It indicates that the trial has progressed into the data-generation phase, bringing the program closer to an efficacy and safety assessment that could shape pipeline prioritization and regulatory planning.
Low Financial LeverageVery low leverage gives Eupraxia greater financial flexibility than a development company carrying substantial debt. The sizeable equity base can support continued research and clinical activity without adding significant interest obligations, although future funding needs remain tied to pipeline progress.
Bears Say
Pre-revenue Business ModelWith no reported revenue, Eupraxia has not yet demonstrated commercial demand or an operating revenue stream to fund its activities. The company therefore remains dependent on successful clinical development, regulatory progress, and eventual product launches before its business model can become self-financing.
Widening Net LossesThe widening loss trajectory shows that operating expenses are increasing faster than any current revenue contribution, consistent with substantial development spending. Persistent losses can erode the equity base over time and increase the amount of capital required before commercial products generate meaningful earnings.
Persistent Cash Burn And Funding RelianceNegative operating and free cash flow mean clinical and corporate activities are consuming real cash rather than merely reflecting non-cash accounting charges. Until revenue begins, Eupraxia must continue securing external financing, creating ongoing dilution or funding-risk pressure over the next several quarters.
Eupraxia Pharmaceuticals News
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was C$7.35 and its highest was C$13.08 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is C$712.55M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 18 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Aug 11, 2026. The company reported -C$0.31 earnings per share for the quarter, beating the consensus estimate of -C$0.314 by C$0.004.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.37.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 65,906,630 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -C$0.31 in its last earnings report, beating expectations of -C$0.314. Following the earnings report the stock price went down -2.781%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:EPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eupraxia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$23.91 (134.38% Upside)
C$23.91 (134.38% Upside)
Blogger Sentiment
Bullish
TSE:EPRX Sentiment 67%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth C$210.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.9%
Last 30 Days ▲ 17.4%
Last 30 Days ▲ 17.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.39%
12-Months-Change
Fundamentals
Return on Equity
-45.29%
Trailing 12-Months
Asset Growth
516.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an extended-release anesthetic designed for extended post-operative pain relief. Furthermore, the company is actively developing product candidates for oncology applications. Established in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals Inc. was formerly known as Plaza Capital Partners Inc. until its renaming in May 2012.
EPRX Stock 12 Month Forecast
Average Price Target
C$23.91
▲(134.38% Upside)